NO20014890L - Fremgangsmåte for behandling av schizofreni - Google Patents

Fremgangsmåte for behandling av schizofreni

Info

Publication number
NO20014890L
NO20014890L NO20014890A NO20014890A NO20014890L NO 20014890 L NO20014890 L NO 20014890L NO 20014890 A NO20014890 A NO 20014890A NO 20014890 A NO20014890 A NO 20014890A NO 20014890 L NO20014890 L NO 20014890L
Authority
NO
Norway
Prior art keywords
cells
schizophrenia
therapeutic cells
treatment
eps
Prior art date
Application number
NO20014890A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014890D0 (no
Inventor
Richard C Allen
Michael Cornfeldt
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of NO20014890D0 publication Critical patent/NO20014890D0/no
Publication of NO20014890L publication Critical patent/NO20014890L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Telephonic Communication Services (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20014890A 1999-04-09 2001-10-08 Fremgangsmåte for behandling av schizofreni NO20014890L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/289,576 US7115256B1 (en) 1999-04-09 1999-04-09 Methods of treating schizophrenia
PCT/US2000/007514 WO2000061156A2 (fr) 1999-04-09 2000-03-20 Methodes de traitement de la schizophrenie

Publications (2)

Publication Number Publication Date
NO20014890D0 NO20014890D0 (no) 2001-10-08
NO20014890L true NO20014890L (no) 2001-12-05

Family

ID=23112130

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014890A NO20014890L (no) 1999-04-09 2001-10-08 Fremgangsmåte for behandling av schizofreni

Country Status (18)

Country Link
US (2) US7115256B1 (fr)
EP (1) EP1165100B1 (fr)
JP (1) JP2003532621A (fr)
AT (1) ATE349218T1 (fr)
AU (1) AU778494B2 (fr)
CA (1) CA2369439A1 (fr)
CY (1) CY1106371T1 (fr)
DE (1) DE60032590T2 (fr)
DK (1) DK1165100T3 (fr)
ES (1) ES2275501T3 (fr)
HK (1) HK1040054B (fr)
IL (3) IL145815A0 (fr)
MX (1) MXPA01010131A (fr)
NO (1) NO20014890L (fr)
NZ (1) NZ514652A (fr)
PT (1) PT1165100E (fr)
WO (1) WO2000061156A2 (fr)
ZA (1) ZA200108251B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
EP1642586A4 (fr) * 2003-06-06 2009-06-17 Kringle Pharma Inc Preparations contenant des cellules
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US7940978B2 (en) * 2007-06-05 2011-05-10 General Electric Company Automatic characterization of cellular motion
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US20100060713A1 (en) * 2008-09-10 2010-03-11 Eastman Kodak Company System and Method for Enhancing Noverbal Aspects of Communication
KR20120007139A (ko) * 2010-07-14 2012-01-20 주식회사 파미니티 탄소나노튜브를 유효성분으로 함유하는 뇌질환 예방 또는 치료용 조성물
WO2014128882A1 (fr) * 2013-02-21 2014-08-28 医療法人 和楽会 Agent thérapeutique pour la dépression anxieuse
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3803866A4 (fr) 2018-05-24 2022-03-16 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464816B (sv) 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5447948A (en) 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
DK0755258T3 (da) 1994-04-13 2002-05-13 Res Corp Technologies Inc Fremgangsmåde til behandling af sygdom ved at anvende Sertoli-celler og allo-transplantater eller xeno-transplantater
AU7963998A (en) 1997-06-13 1998-12-30 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
EP1044024A1 (fr) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Utilisation de cellules epitheliales retiniennes pigmentees pour la creation d'un site d'acception immunitaire
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia

Also Published As

Publication number Publication date
IL177538A0 (en) 2006-12-10
EP1165100B1 (fr) 2006-12-27
CA2369439A1 (fr) 2000-10-19
IL145815A (en) 2008-12-29
NO20014890D0 (no) 2001-10-08
ES2275501T3 (es) 2007-06-16
JP2003532621A (ja) 2003-11-05
WO2000061156A2 (fr) 2000-10-19
PT1165100E (pt) 2007-02-28
US7115256B1 (en) 2006-10-03
AU3907100A (en) 2000-11-14
NZ514652A (en) 2004-06-25
CY1106371T1 (el) 2011-10-12
HK1040054A1 (en) 2002-05-24
DK1165100T3 (da) 2007-05-07
IL145815A0 (en) 2002-07-25
AU778494B2 (en) 2004-12-09
MXPA01010131A (es) 2002-08-20
DE60032590T2 (de) 2007-10-11
EP1165100A2 (fr) 2002-01-02
HK1040054B (en) 2007-08-10
WO2000061156A3 (fr) 2001-01-25
DE60032590D1 (de) 2007-02-08
ZA200108251B (en) 2002-12-24
US20060292128A1 (en) 2006-12-28
ATE349218T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
CY1106371T1 (el) Μεθοδοι αγωγης της σχιζοφρενειας
MXPA03006863A (es) Derivados de oxazolilpirazol com inhibidores de cinasa.
CL2009000380A1 (es) Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras.
CL2007001733A1 (es) Compuestos derivados de imidazol condensado con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
MY159955A (en) Certain chemical entities, compositions and methods
MX2010002319A (es) Derivados indolicos 2,3 sustituidos para el tratamiento de infecciones virales.
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
NO20052739L (no) CCR5-antagonister som medikamenter
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
NO20072984L (no) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
ATE384724T1 (de) Cyclopropylverbindungen als ccr5 antagonisten
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
TNSN07240A1 (en) Compounds for flaviviridae treatment
NO20021541L (no) 5-beta-sapogenin- og pseudosapogeninderivater samt deres anvendelse ved behandling av demens
GB0222514D0 (en) Organic compounds
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application